Protagonist Therapeutics PTGX Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's cash ratio?
- Protagonist Therapeutics (PTGX) reported cash ratio of 5.6× in Q1 2026.
- How has Protagonist Therapeutics's cash ratio changed year-over-year?
- Protagonist Therapeutics's cash ratio increased by 41.0% year-over-year, from 4× to 5.6×.
- What is the long-term trend for Protagonist Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's cash ratio has grown at a -0.6% compound annual growth rate (CAGR), from 2.9× to 2.8×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.